2019 Paroxysmal Supraventricular Tachycardia Pipeline Insights Report - ResearchAndMarkets.com

The "Paroxysmal Supraventricular Tachycardia- Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

A detailed picture of the Paroxysmal Supraventricular Tachycardia pipeline landscape is provided which includes the disease overview and Paroxysmal Supraventricular Tachycardia treatment guidelines.

The assessment part of the report embraces, in depth Paroxysmal Supraventricular Tachycardia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Paroxysmal Supraventricular Tachycardia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Paroxysmal Supraventricular Tachycardia Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Paroxysmal Supraventricular Tachycardia targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Paroxysmal Supraventricular Tachycardia pipeline report covers 10+ companies. Some of the key players include Milestone Pharmaceuticals (Etripamil) etc.

Scope of the report

• The Paroxysmal Supraventricular Tachycardia report provides an overview of therapeutic pipeline activity for Paroxysmal Supraventricular Tachycardia across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Paroxysmal Supraventricular Tachycardia therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Paroxysmal Supraventricular Tachycardia Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Paroxysmal Supraventricular Tachycardia

Key Topics Covered:

1. Report Introduction

2. Paroxysmal Supraventricular Tachycardia (Supraventricular tachycardia (SVT))

2.1. Paroxysmal Supraventricular Tachycardia Disease Overview

2.2. Paroxysmal Supraventricular Tachycardia History

2.3. Paroxysmal Supraventricular Tachycardia Symptoms

2.4. Paroxysmal Supraventricular Tachycardia Causes

2.5. Paroxysmal Supraventricular Tachycardia Pathophysiology

2.6. Paroxysmal Supraventricular Tachycardia Diagnosis

2.6.1. Diagnostic Guidelines

3. Paroxysmal Supraventricular Tachycardia Current Treatment Patterns

3.1. Treatment Guidelines

4. Paroxysmal Supraventricular Tachycardia- An Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Paroxysmal Supraventricular Tachycardia companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Paroxysmal Supraventricular Tachycardia Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis

4.1.2.2. Paroxysmal Supraventricular Tachycardia Acquisition Analysis

4.2. Clinical Assessment of Pipeline Drugs

4.2.1. Assessment by Phase of Development

4.2.2. Assessment by Product Type (Mono/Combination)

4.2.3. Assessment by Route of Administration

4.2.4. Assessment by Molecule Type

4.2.5. Assessment by MOA

5. Paroxysmal Supraventricular Tachycardia Pipeline Therapeutics

5.1. Late Stage Products (Phase-III)

5.2. Mid Stage Products (Phase-II)

5.3. Early Stage Products (Phase-I)

5.4. Pre-clinical and Discovery Stage Products

5.5. Inactive Products

6. Paroxysmal Supraventricular Tachycardia -Products Analysis

6.1. Product Profiles

6.1.1. Etripamil- Milestone Pharmaceuticals

6.1.1.1. Product Description

6.1.1.1.1. Product Overview

6.1.1.1.2. Mechanism of Action

6.1.1.2. Research and Development

6.1.1.2.1. Clinical Studies

6.1.1.2.1.1. Detailed Study Description

6.1.1.2.1.2. Study Results

6.1.1.2.1.3. Clinical Trials: Tabular View

6.1.1.3. Product Development Activities

6.1.1.3.1. Tabulated Product Summary

6.1.1.3.1.1. General Description Table

7. Recent Technologies

8. Paroxysmal Supraventricular Tachycardia Key Companies

8.1. Milestone Pharmaceuticals

8.2. Cordex Pharma

8.3. CV Therapeutics

8.4. Procter & Gamble

8.5. Novartis

8.6. AOP Orphan Pharmaceuticals AG

9. Paroxysmal Supraventricular Tachycardia Key Products

9.1. Etripamil

9.2. Adenosine triphosphate injection

9.3. Tecadenoson

9.4. Lappaconitine

9.5. SDZ WAG 994

9.6. Landiolol

10. Dormant and Discontinued Products

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. Paroxysmal Supraventricular Tachycardia- Unmet Needs

12. Paroxysmal Supraventricular Tachycardia- Future Perspectives

13. Appendix

Companies Mentioned

• Milestone Pharmaceuticals
• 3M Pharmaceuticals
• Cordex Pharma
• Eisai
• CV Therapeutics
• Procter & Gamble
• Novartis
• Pfizer
• Ono Pharmaceutical
• AOP Orphan Pharmaceuticals AG
• Pfizer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/mkb0jf

View source version on businesswire.com: https://www.businesswire.com/news/home/20191021005475/en/